Overview of
The Dr. Nalin Nag
Lung Cancer Rare Mutations
Clinical Trials Program Program
Thanks to the support of ICAN Donors, the Dr. Nalin Nag Lung Cancer Rare Mutations Program will help foster clinician education on rare muations and clinical trials.
ICAN patients involved in the Dr. Nalin Nag Lung Cancer Rare Mutations Program have access to the following information services:
- Direct Navigation of Exon 20 Insertion Cases, both EGFR Exon 20 Insertions and HER2 Exon 20 Insertions;
- Patient-Reported Outcomes Surveys of our Exon 20 and Rare Cancers Communities;
- Cutting-Edge Research at Top Laboratories Focusing on Exon 20 Resistance Mutations
- Public Policy Initiatives to Accelerate the Rare Lung Cancer Treatment Pipeline
- Health Information Technology Initiatives
- National, Global, and Country-by Country Sequencing and Profiling Campaigns to Identify Exon 20 Insertions and Point Mutations on Diagnosis.
For additional information, please contact Marcia at (602) 618-0183 or please email DrNalinNagProgram@askican.org. Thank you!
The Dr. Nalin Nag Rare Mutations Clinical Trials Program Program
is a vital part of ICAN's Cancer Patient Advocacy and Clinical Trials Program Advocacy Services.
For more information about this special program, please click on.....
If you would like to become involved as a donor and supporter or a member of our Cancer Research Literature team as a Research Team Leader (medical school students, physicians, nurses, and post-docs only please), you may reach us at DrNalinNagProgram@askican.org.
Federal Tax I.D.: EIN 86-0818253 | WA Charities: 37195